Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,885 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07638371RecruitingPhase 1
MSK-TCR5 Cell Therapy for RAS G12D Solid Tumors
This study tests a new type of cell therapy called MSK-TCR5, designed to fight solid cancers (like pancreatic, lung, or colon cancer) that have a specific RAS G12D mutation. The therapy uses your own immune cells trained to recognize and attack cancer cells with this mutation.
Basking Ridge, New JerseyAges 18 years+ - NCT07638774Recruiting
Compression Gloves and Socks to Prevent Nerve Damage from UTD1 Cancer Drug
This study tests whether wearing special compression and cooling gloves and socks can help prevent nerve damage (numbness and tingling in hands and feet) that sometimes occurs in women receiving a breast cancer medication called UTD1. You would wear these gloves and socks during and after your chemotherapy treatment.
ShanghaiAges 18–75 - NCT07660627Recruiting
ctDNA test for tracking cancer after treatment
This trial uses a blood test to find tiny bits of tumor DNA after treatment. It helps doctors see if any cancer remains, which could guide next steps for people with esophageal, stomach, or pancreatic cancer.
BrnoAges Any age - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT07356466Enrolling by invitationEarly Phase 1
Combination therapy vs. standard chemo for advanced stomach cancer
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Fuzhou, FujianAges 18–75 - NCT06957678Enrolling by invitation
AI predicts lymph node spread in stomach cancer using scans and biopsy
This study uses artificial intelligence to predict whether stomach cancer has spread to nearby lymph nodes. By analyzing your CT/MRI scans and biopsy results before surgery, the AI may help doctors plan your treatment more precisely.
Shijiazhuang, None SelectedAges 18–80 - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT04615013RecruitingPhase 1
NBTXR3 with chemoradiation for esophageal cancer treatment
This early-phase study tests adding NBTXR3 (a special treatment given into the tumor) to standard chemotherapy and radiation for esophageal cancer. The goal is to see if it can improve cancer control and to learn about safety and dosing.
Houston, TexasAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT04693377Recruiting
Freezing tumor treatment plus targeted radiation for painful bone spread
This study tests whether combining a “freezing” procedure (cryoablation) with focused external radiation (SBRT) can reduce pain from bone metastases. It’s for people with certain cancers that have spread to bone and are having significant pain in a specific bone spot.
Houston, TexasAges 18 years+ - NCT05172245RecruitingPhase 1
Testing a new drug added to chemoradiation for head and neck cancer
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
Tampa, FloridaAges 18 years+ - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT06636734RecruitingPhase 2
Lovastatin plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
Atlanta, GeorgiaAges 18 years+ - NCT06868433RecruitingPhase 1
TMV vaccine alone or with pembrolizumab for advanced HNSCC
This trial tests a vaccine made from your own tumor to help your immune system fight head and neck cancer that has returned or spread. It is given alone or with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors or slow progression.
Atlanta, GeorgiaAges 18 years+ - NCT06078709RecruitingPhase 2
Pre-surgery radiation and chemo for esophageal cancer
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Tucson, ArizonaAges 18 years+ - NCT04329494RecruitingPhase 1
Study of targeted drug delivery into the abdomen using PIPAC
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Duarte, CaliforniaAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT06165419RecruitingPhase 2
High-dose radiation for spine metastases from solid tumors
This trial tests a new way of giving high-dose radiation to solid tumors that have spread to the spine. It is for people whose spine is stable, have not had prior treatment to that area, and have only minor weakness (if any).
Stony Brook, New YorkAges 18 years+ - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Little Rock, ArkansasAges 18 years+ - NCT07215988Recruiting
Studying insurance for skin cancer treatment
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
Columbus, OhioAges 18 years+ - NCT07043608RecruitingPhase 2
Zanzalintinib for kidney cancer that spread to bone
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
San Francisco, CaliforniaAges 18 years+ - NCT06571734RecruitingPhase 2
XL092 for advanced sarcoma types
This trial tests an experimental drug called XL092 (zanzalintinib) for people with advanced leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is a type of targeted therapy that may stop cancer growth.
Chicago, IllinoisAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,885 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.